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Abstract
Objective:  To  elucidate  whether  insulin  is  effective  or  not  in  patients  with  cystic  ﬁbrosis  before
the diabetes  mellitus  phase.
Data  source:  The  study  was  performed  according  to  the  Prisma  method  between  August  and
September  2014,  using  the  PubMed,  Embase,  Lilacs  and  SciELO  databases.  Prospective  studies
published in  English,  Portuguese  and  Spanish  from  2002  to  2014,  evaluating  the  effect  of  insulin
on weight  parameters,  body  mass  index  and  pulmonary  function  in  patients  with  cystic  ﬁbrosis,
with a  mean  age  of  17.37  years  before  the  diabetes  mellitus  phase  were  included.
Data synthesis: Eight  articles  were  identiﬁed  that  included  180  patients  undergoing  insulin  use.
Sample size  ranged  from  4  to  54  patients,  with  a  mean  age  ranging  from  12.4  to  28  years.
The type  of  follow-up,  time  of  insulin  use,  the  dose  and  implementation  schedule  were  very
heterogeneous  between  studies.
Conclusions:  There  are  theoretical  reasons  to  believe  that  insulin  has  a  beneﬁcial  effect  in  the
studied population.  The  different  methods  and  populations  assessed  in  the  studies  do  not  allow
us to  state  whether  early  insulin  therapy  should  or  should  not  be  carried  out  in  patients  with
cystic ﬁbrosis  prior  to  the  diagnosis  of  diabetes.  Therefore,  studies  with  larger  samples  and
insulin use  standardization  are  required.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).ntes  com  ﬁbrose  cística  na  fase  de  pré-diabetes:  uma  revisãoPALAVRAS-CHAVE Insulinoterapia  em  pacie
Fibrose  cística;
Insulina;
Diabetes  melito
sistemática
Resumo
Objetivo:  Elucidar  se  a  insulina  é  eﬁcaz  ou  não  em  pacientes  com  ﬁbrose  cística  antes  da  fase
de diabetes.
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license (http://creativecommons.org/licenses/by/4.0/).
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Fontes  de  dados:  O  estudo  foi  feito  de  acordo  com  o  método  Prisma  entre  agosto  e  setembro  de
2014, nas  bases  de  dados  PubMed,  Embase,  Lilacs  e  SciELO.  Foram  incluídos  estudos  prospectivos
publicados  em  inglês,  português  e  espanhol  de  2002  a  2014  que  avaliaram  o  efeito  da  insulina
nos parâmetros  peso,  índice  de  massa  corporal  e  func¸ão  pulmonar,  em  pacientes  com  ﬁbrose
cística, com  média  de  17,37  anos,  antes  da  fase  de  diabetes.
Síntese  dos  dados:  Foram  identiﬁcados  oito  artigos  que  incluíram  180  indivíduos  submetidos
ao uso  de  insulina.  O  tamanho  das  amostras  variou  de  4  a  54  pacientes,  idade  média  entre
12,4 e  28  anos.  O  tipo  de  acompanhamento,  o  tempo  de  uso  de  insulina,  a  dose  e  o  cronograma
de implementac¸ão  foram  muito  heterogêneos  entre  os  estudos.
Conclusões:  Existem  razões  teóricas  para  se  acreditar  que  a  insulina  tenha  um  efeito  benéﬁco
na populac¸ão  estudada.  Os  diferentes  métodos  e  populac¸ões  encontrados  não  permitem  aﬁrmar
se a  terapia  precoce  com  insulina  deve  ou  não  ser  feita  em  pacientes  com  ﬁbrose  cística  pre-
viamente ao  diagnóstico  de  diabetes.  Portanto,  são  necessários  estudos  com  amostras  maiores
e uniformidade  de  uso  da  insulina.
©  2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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ters  (weight  or  height  or  body  mass  index  and  pulmonaryntroduction
ystic  ﬁbrosis-related  diabetes  (CFRD)  is  the  most  common
omorbidity  in  patients  with  cystic  ﬁbrosis  (CF)  and  affects
0%  of  adolescents  and  40--50%  of  adults  with  CF.1
Glucose  disorders  in  CF  patients  typically  begin  with
n  intermittent  postprandial  hyperglycemia,  followed  by
ral  glucose  intolerance  without  fasting  hyperglycemia  and
nally  diabetes  with  fasting  hyperglycemia.2,3
Insulin  deﬁciency  and  resulting  hyperglycemia  affect  lung
isease.3--5 Insulin  is  a  hormone  with  anabolic  effects  and  its
eﬁciency  may  have  a  negative  clinical  impact  on  patients
onsidered  ‘‘prediabetic’’.6 Increased  serum  glucose  levels
≥144mg/dL)  may  have  an  adverse  effect  on  lung  function.
urthermore,  increased  glucose  in  the  bronchial  tree  favors
he  growth  of  respiratory  pathogens.5 There  is  still  a  loss  of
ean  body  mass  due  to  the  catabolic  state  caused  by  insulin
eﬁciency,  which  leads  to  a  consumption  of  fat  and  proteins
nd  also  affects  pulmonary  function.7
Therefore,  insulin  deﬁciency  promotes  a  clinical  deteri-
ration  in  this  population  and  not  only  an  abnormal  glucose
etabolism,  which  may  be  enhanced  by  early  intervention
ith  insulin.6 Both  diabetes  and  glucose  intolerance  reduce
he  life  expectancy  of  CF  patients;  insulin  is  the  only  treat-
ent  that  improves  clinical  outcomes.8 Early  treatment  with
nsulin  may  reduce  the  morbidity  and  mortality  of  the  under-
ying  disease.9,10
Moreover,  CF  patients’  classiﬁcation  using  the  oral  glu-
ose  tolerance  test  (OGTT)  in  intolerant  and  diabetic
atients  is  based  on  criteria  derived  from  epidemiologi-
al  studies  in  non-CF  subjects,  it  raises  doubts  whether
hese  conventional  diagnostic  limits  would  be  appropriate
r  relevant  for  CF  patients.11 Thus,  the  use  of  conventional
lucose  evaluation  tests  in  the  CF  population  could  under-
stimate  the  number  of  patients  with  abnormal  glucose
etabolism,  and,  consequently,  this  group  could  beneﬁtrom  early  intervention  with  insulin,  in  glucose  levels  below
hose  considered  abnormal  in  populations  without  cystic
brosis.12
f
n
ATo  our  knowledge,  there  is  no  systematic  review  of  early
nitiation  of  insulin  therapy  in  CF  patients.  Therefore,  the
im  of  this  study  was  to  identify  the  effects  of  this  interven-
ion  and  contribute  to  clinical  practice  and  future  studies.
ethod
he  search  process  was  developed  according  to  the  Prisma
ethod  (Preferred  Reporting  Items  for  Systematic  Reviews
nd  Meta-Analyses).13 The  search  was  conducted  between
ugust  and  September  2014  in  the  following  electronic
atabases:  PubMed,  Lilacs,  SciELO,  and  Excerpta  Medica
atabase  (Embase).
The  following  terms  and  descriptors  (Medical  Subjects
eadings  --  MeSH)  were  used  for  the  search:  ‘cystic  ﬁbro-
is’,  ‘early  insulin’,  ‘insulin’,  ‘body  mass  index’,  ‘impaired
lucose  tolerance’,  and  ‘therapy’;  in  combinations:  ‘cystic
brosis  and  early  insulin’,  ‘cystic  ﬁbrosis  and  insulin  and
ody  mass  index’,  ‘cystic  ﬁbrosis  and  early  insulin’,  ‘cystic
brosis  and  insulin  and  body  mass  index’,  ‘impaired  glucose
olerance  and  cystic  ﬁbrosis  and  insulin  and  therapy’.
Studies  published  between  2002  and  2014  were  identi-
ed  through  electronic  search  by  two  independent  reviewers
ho  evaluated  the  titles  and  abstracts  of  articles.  Refer-
nces  of  selected  articles  were  also  reviewed  in  order  to
dentify  studies  not  found  in  the  surveyed  bases.  Discrep-
ncies  between  reviewers  were  discussed  and  resolved  by
onsensus.  The  date  of  the  ﬁrst  search  was  August  28,  2014,
nd  the  last,  September  22,  2014.
Inclusion  criteria  were:  (I)  original  articles;  (II)  prospec-
ive  studies;  (III)  articles  in  English,  Spanish  or  Portuguese;
IV)  cystic  ﬁbrosis  diagnosis;  (V)  glucose  disorders;  (VI)
nsulin  use  (regardless  of  type,  dose,  or  implementation
chedule);  (VII)  evaluation  of  the  results  in  clinical  parame-unction).  Glucose  disorder  was  considered  as  an  OGTT
on-characterized  as  diabetes  by  the  American  Diabetes
ssociation  (ADA)  criteria  and  OGTT  glucose  values  above
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140mg/dL  at  any  time,  except  at  baseline  and  120min;
or  postprandial  glucose  random  or  above  200mg/dL;  or
impaired  glucose  tolerance  (IGT)  diagnosis  by  ADA  criteria.14
Exclusion  criteria  were:  (I)  non-original  articles,  such  as
letters,  conference  proceedings  and  editorials;  (II)  studies
evaluated  only  CFRD  without  other  types  of  disorders  of
glucose.
The  extracted  data  were:  study  design;  sample  size;
population  characteristics;  follow-up  time;  type  of  insulin
therapy  (including  dose  and  regime  used);  and  effects  on
weight,  body  mass  index,  and  lung  function.
Results
The  initial  search  identiﬁed  508  articles,  of  which  111
were  selected  based  on  titles  and  abstracts.  References  of
selected  papers  were  also  reviewed  and  an  additional  study
was  included.  Of  these,  80  were  identiﬁed  as  duplicates  and
removed;  thus,  32  articles  were  read  in  full,  of  which  24
were  excluded  by  the  exclusion  criteria.  The  ﬁnal  selection
consisted  of  eight  items  (Fig.  1).  Characteristics  of  the  study
results  are  summarized  in  Table  1.
Sample  size  of  the  included  studies  ranged  from  4  to  54
patients,  with  mean  age  from  12.4  to  28  years.  Investigators
and  subjects  were  not  blind  to  the  treatment  assignment  in
any  of  the  studies.
Type  of  follow-up,  insulin  time,  dose,  and  implementa-
tion  schedule  were  very  heterogeneous,  which  can  be  seen
in  Table  1.  Three  studies  used  control  groups  to  compare  the
effects  of  insulin.  Moran  et  al.15 selected  corresponding  con-
trols  who  underwent  other  types  of  intervention  (repaglinide
or  placebo),  while  Minicucci  et  al.16 used  controls  with  IGT
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Full-text articles assessed for
eligibility (n=31)
Full-text articles read in full (n=32)
Articles included (n=8)
Selected abstracts (n=111)
Records identified through
database search
(n=508)
Figure  1  Flowchart  of  study  identiﬁcation  with  inclusions  as  stage  369
nd  Kolousˇková  et  al.17 used  controls  with  normal  OGTT  by
DA  criteria  (NGT).  In  these  last  two  studies,  controls  did
ot  undergo  pharmacological  interventions.
Inclusion  criteria  for  studies  were  very  heterogeneous.
ozzillo  et  al.18 used  the  following  inclusion  criteria:  no  use
f  systemic  corticosteroids  and  no  exacerbation  of  lung  dis-
ase.  Minicucci  et  al.16 included  patients  with  at  least  one
f  the  following  conditions:  (I)  body  mass  index  BMI<10th
ercentile  (p10);  (II)  loss  of  one  BMI  percentile  for  age  and
ex  in  the  previous  year;  (III)  forced  expiratory  volume  in
ne  second  (FEV1)  ≤80%  of  predicted;  and  (IV)  decreased
EV1≥10%  in  the  previous  year.  Lung  function  deterioration
nd  weight  loss  were  also  criteria  for  inclusion  of  subjects  in
he  study  by  Dobson  et  al.6 In  contrast,  Moran  et  al.15 chose
o  intervene  in  a  more  clinically  stable  group  of  patients  and
sed  the  following  inclusion  criteria:  (I)  end  of  linear  growth;
II)  weight  stability  in  the  last  three  months;  (III)  absence  of
cute  infection  in  the  last  two  months.  Exclusion  criteria  for
his  study  were:  (I)  use  of  oral  or  intravenous  corticosteroids
n  the  last  six  months;  (II)  fasting  hyperglycemia  in  the  previ-
us  year;  (III)  liver  dysfunction;  (IV)  pregnancy.  Early  insulin
eﬁciency,  diagnosed  by  intravenous  glucose  tolerance  test
IVGTT)  and/or  high  levels  of  glucose  in  OGTT,  was  used  as
nclusion  criteria  in  the  studies  by  Kolousˇková  et  al.17 and
ameed  et  al.19
Five  studies  evaluated  the  effects  of  insulin  in  BMI  of
F  patients.15--18,20 Bizzarri  et  al.,20 Moran  et  al.,15 and
olousˇková  et  al.17 demonstrated  a  signiﬁcant  increase  in
18MI  after  insulin  intervention.  Mozillo  et  al. found  a  sig-
iﬁcant  increase  in  BMI  only  in  patients  with  initial  BMI
-score  <−1.  Although  Moran  et  al.15 identify  improvements
n  BMI  in  the  group  as  a  whole,  in  particular  IGT  group
Deleted duplicate articles (n=80)
Additional records identified through
references (n=1)
Excluded full-text articles read
in full (n=24)
Studies that include only
CFRD* (n=7)
Studies that did not use
insulin (n=11)
Retrospective studies (n=1)
Letters, conference proceedings or
editorial (n=5)
nd  exclusions  (cystic  ﬁbrosis-related  diabetes  --  *CFRD).
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Table  1  Characteristics  of  included  studies.
Population  Intervention  Results
Sample
characteristics
Mean  follow-up
(months)
Mean  age  (years)
(min--max)
Insulin  type  and
average  dose
BMI  FEV1
Dobson  et  al.6 Normal  OGTT
glucose  and
postprandial
>200mg/dL
3  20.25
(15--23)
NPH  6-8UI/d
ou  UR
5UI/d+7UI/d
(70/30)
NA NSg
Case  report  (n=4)
Bizzarri  et  al.20 IGT 16.8  18.2
(9.2--27.8)
Glargine
0.3UI/kg/d
SI  SI
Clinical uncontrolled
trial  (n=6)
p=0.026 p=0.027
Mozzillo  et  al.18 2:  CFRDFH+ 12 12.4
(2.6--19)
Glargine
0.23UI/kg/d
SId SI
Clinical uncontrolled
trial  (n=22)
7:  CFRDFH−
9: IGT  p=0.017  p=0.01
4a
Moran  et  al.15 23:  CFRDFH− 12  28±9  Aspart
0.5UI:  15gCHO
SIe NS
Randomized
controlled trial
(n=30)
7:  severe  IGT b p=0.02
Kolousˇková et  al.17 17:  CFRDFH−
11:  IGT
36 15.3c
(11.1--20.6)
NPH
0.12--0.25UI/kg/d
SIf SIh
Randomized
controlled  trial
(n=28)
p<0.05  p=0.03
Drummond et  al.12 24:  CFRD 69.36 27.64
(16--52)
UR,  premixed,
basal  and
basal-bolus
NA NS
Clinical
uncontrolled  trial
(n=54)
18:  IGT
12:  NGT
Hameed  et  al.19 2:  CFRDFH+ 9.6  12.5
(7.2--18.1)
Detemir
0.13UI/kg/d
NA  SI
Clinical
uncontrolled
trial (n=18)
4:  CFRDFH−
6: IGT  p=0.007
6: NGT
Minicucci  et  al.16 IGT  18  18
(11--53)
Glargine
0.1--0.15UI/kg/d
NS  NS
Randomized
controlled
multicenter  clinical
trial  (n=18)
CFRDFH+, CFRD with fasting hyperglycemia; CFRDFH−, CFRD without fasting hyperglycemia; NGT, normal glucose tolerance; CHO,
carbohydrate; FEV1, forced expiratory volume in one second; UR, ultrafast insulin; NA, data not evaluated; NS, not signiﬁcant; SI,
signiﬁcant increase.
a One or more of OGTT values >140mg/dL (between T30 and T90).
b OGTT >200mg/dL at any time and 180--199mg/dL 120min.
c Median.
d Only in group with initial Z-score <−1.
e Only CFRDFH− group.
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g Increase suggested, but without statistical evaluation.
h Compared with control group (there was no statistical differen
hey  did  not  notice  a  signiﬁcant  increase  in  this  parame-
er.  Dobson  et  al.,6 Drummond  et  al.,12 and  Hameed  et  al.19
hose  to  assess  body  weight.  Hameed  et  al.19 and  Drummond
t  al.12 found  signiﬁcant  weight  gain  after  insulin  interven-
ion,  while  Dobson  et  al.6 suggested  this  trend,  as  data  were
ot  statistically  evaluated.
FEV1  was  the  only  clinical  parameter  assessed  by  all  stud-
es.  Bizzarri  et  al.,20 Mozzillo  et  al.,18 and  Hameed  et  al.19
ound  a  signiﬁcant  increase  in  FEV1  after  the  use  of  insulin.
olousˇková  et  al.17 found  that,  at  the  end  of  follow-up,  inter-
ention  group  had  higher  FEV1  compared  to  control  group.
u
(
a
ltragroup).
obson  et  al.6 showed  an  apparent  increase  in  this  param-
ter  with  the  use  of  insulin,  as  it  was  only  a case  report.  In
tudies  by  Moran  et  al.,15 Drummond  et  al.12 and  Minicucci
t  al.,16 FEV1  remained  unchanged  after  the  intervention.
ut  Drummond  et  al.12 evaluated  separately  only  patients
iagnosed  with  IGT  and  found  a  signiﬁcant  reduction  in  FEV1
ecline  rate  in  patients  using  insulin.  Hameed  et  al.19 eval-
ated  separately  only  the  early  insulin-deﬁcient  patients
excluding  patients  with  CFRD)  and  also  found  in  this  group
 signiﬁcant  increase  in  FEV1.  Moran  et  al.15 reported  a
ower  apparent  decline  in  FEV1  in  patients  using  insulin
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compared  to  placebo,  but  this  stability  was  not  statistically
signiﬁcant.
Mozzillo  et  al.18 found  a  reduced  number  of  pulmonary
exacerbations  (as  compared  to  the  previous  year),  while
Bizzarri  et  al.20 found  no  changes  in  the  number  of  hospi-
talizations  for  exacerbations.  The  four  patients  evaluated
by  Dobson  et  al.6 showed  an  increase  in  forced  vital  capac-
ity  (FVC)  with  the  use  of  insulin.  Hameed  et  al.19 found  a
signiﬁcant  improvement  in  FVC  after  the  intervention.
In  the  results  found  by  Bizzarri  et  al.,20 there  was  no
signiﬁcant  change  in  the  levels  of  glycosylated  hemoglobin
(HbA1c)  after  insulin,  whereas  the  group  of  patients  evalu-
ated  by  Minicucci  et  al.16 showed  a  signiﬁcant  reduction  in
HbA1c  with  the  use  of  insulin.
Frequent  episodes  of  hypoglycaemia  were  reported  only
by  Drummond  et  al.12 In  the  other  studies  cited  in  this
review,  the  adverse  effects  of  insulin  therapy  were  infre-
quent  and  well  tolerated.
Discussion
There  are  few  published  papers  on  the  use  of  insulin  in
patients  with  cystic  ﬁbrosis  prior  to  overt  diabetes.  Most
are  limited  to  a  single  center  and  mainly  to  adults.  To  our
knowledge,  this  is  the  ﬁrst  systematic  review  to  examine
the  beneﬁts  and  risks  of  insulin  use  in  CF  patients  before
the  diagnosis  of  diabetes.
Glucose  intolerance  indicates  the  presence  of  insulin
deﬁciency,  which  leads  to  a  protein  consumption  and  nega-
tive  clinical/nutritional  impact.  Therefore,  early  treatment
of  insulin  can  have  a  positive  effect  in  CF  patients  in  the
prediabetic  phase.20
The  study  results  make  sense  when  considering  the
pathophysiology  of  the  evolution  to  CFRD.  Initially,  there
is  an  insulin  deﬁciency  that  generates  a  protein  catabolism
and  glycemic  excursions,  with  consequent  difﬁculty  gaining
and  maintaining  weight  and  worsening  of  lung  func-
tion.  Therefore,  the  introduction  of  insulin  at  this  stage
would  likely  prevent  the  catabolic  effects  of  insulin
deﬁciency.
Current  data  are  clear  about  the  insulin  treatment  for
patients  with  CFRD  with  or  without  fasting  hyperglycemia,14
but  there  are  no  consistent  results  to  determine  whether  this
treatment  should  also  be  used  for  those  with  other  glucose
disorders,  as  it  is  not  well  deﬁned  what  are  glucose  disorders
in  this  speciﬁc  population.  Moreover,  there  is  doubt  whether
the  cut-off  values  for  the  diagnosis  of  CFRD  and  IGT  are  valid
for  CF  because  they  are  based  on  population  without  the
disease.
A  negative  impact  of  the  prediabetic  phase  is  described  in
nutritional  status  and  pulmonary  function  of  CF  patients,6,21
it  suggests  that  insulin  should  be  started  before  the  diagnosis
of  CFRD  by  the  current  methods  available,  as  insulin  has
anabolic  effects  and  these  patients  have  few  side  effects
(hypoglycemia).  The  only  study  reporting  frequent  episodes
of  hypoglycemia  was  the  study  by  Drummond  et  al.,12 but
they  included  several  insulin  therapy  regimens  in  patients
with  CFRD,  IGT,  and  NGT,  and  there  was  no  description  of  the
insulin  type  or  dose  instruction  for  each  group,  which  may  be
related  to  the  difference  in  the  frequency  of  hypoglycemia
seen  between  studies.
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Although  most  studies  have  a small  sample  size  and  used
ore  than  one  type  of  insulin,  only  Moran  et  al.15 and
inicucci  et  al.16 reported  no  positive  effects  with  early
nsulin  therapy,  but  these  studies  have  some  peculiarities
escribed  below,  suggesting  that  early  initiation  of  insulin
herapy  in  CF  patients  could  be  beneﬁcial.
Minicucci  et  al.16 reported  no  clinical  improvement  with
he  use  of  glargine  in  CF  patients  with  IGT  (ADA  crite-
ia).  The  authors  assumed  that  participation  in  the  study
ade  patients  more  aware  of  their  change  in  glucose
etabolism,  leading  to  better  nutritional  behavior.  Most
ther  studies6,17--20 showed  positive  results,  but  the  insulin
oses  used  were  higher.
Mozzillo  et  al.18 found  that  after  12  months  of  therapy
ith  insulin,  BMI  curve  (Centers  for  Disease  Control  --  CDC)
mproved  in  patients  with  baseline  Z-score  below  −1,  which
s  in  agreement  with  the  study  by  Kolousˇková  et  al.17 that
lso  reported  improvement  in  BMI,  regardless  of  the  baseline
-score.
Kolousˇková  et  al.17 demonstrated  that  insulin  administra-
ion  has  positive  effects  on  lean  body  mass  due  to  protein
atabolism  reversal.  However,  control  group  also  showed  a
endency  towards  that  improvement,  probably  due  to  better
utritional  orientation,  as  in  both  groups  there  was  a  rec-
mmendation  for  increased  caloric  intake  up  to  120--150%
f  the  daily  needs.  According  to  the  authors,  the  results
upport  the  concept  that  insulin  deﬁciency,  assessed  in  this
tudy  by  using  IVGTT  and  OGTT,  leads  to  clinical  deteriora-
ion  in  CF  patients  and  that  early  initiation  of  insulin  therapy
ould  be  recommended  earlier  than  it  is  currently  accepted
CFRD).
Dobson  et  al.,6 Bizzarri  et  al.,20 and  Hameed  et  al.19
ound  weight  improvement  in  patients  using  insulin.
Moran  et  al.15 reported  that  insulin  reverses  weight  loss  in
atients  with  CFRD  without  fasting  hyperglycemia,  but  not  in
atients  with  severe  IGT.  However,  the  study  population  was
n  adulthood  and  there  seems  to  be  a  better  response  when
hese  individuals  are  in  childhood  and  adolescence.  More-
ver,  the  group  in  question  had  severe  IGT  (OGTT≥200mg/dL
t  any  time  and  120min  between  180  and  199mg/dL),  and
n  other  studies,  patients  were  previously  selected  in  severe
GT  phase,  which  may  explain  the  differences  found  in  the
esults.
Bizarri  et  al.20 found  improved  FEV1  with  no  reduc-
ion  in  pulmonary  exacerbations.  Mozzillo  et  al.18 reported
ncreased  FEV1  and  reduced  pulmonary  exacerbations  with
he  use  of  insulin.  Hameed  et  al.19 demonstrated  a  fall  in
EV1  before  starting  treatment  and  improvement  after  the
ntroduction  of  insulin.  Kolousˇková  et  al.17 and  Drummond
t  al.12 assessed  FEV1  compared  to  untreated  subjects  and
dentiﬁed  a  decline  in  lung  function  in  control  group,  which
as  not  seen  in  insulin-treated  group.  Moran  et  al.15 and
inicucci  et  al.16 found  no  improvement  in  FEV1  with  early
se  of  insulin.  However,  in  the  study  by  Minicucci  et  al.16
here  was  a  10%  decrease  in  FEV1  in  the  year  prior  to
he  intervention,  which  may  be  a  bias  because  even  CFRD
atients  have  no  such  decline  in  this  parameter.  Kolousˇková
t  al.17 and  Drummond  et  al.12,  who  had  a  more  consistent
umber  of  cases,  found  that  FEV1  was  lower  in  the  untreated
roup  compared  to  those  treated  with  insulin,  which  con-
rms  the  results  described  by  Dobson  et  al.6 Bizarri  et  al.20,
nd  Hameed  et  al.19
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Dobson  et  al.6 suggest  an  improvement  in  pulmonary
unction  (FEV1  and  FVC)  with  the  use  of  insulin.  However,
heir  sample  size  was  small  (n=4),  selected  by  convenience,
nd  had  no  control;  the  reevaluation  occurred  in  a  short
eriod  of  time  (3  months)  without  insulin  standardiza-
ion  (more  than  one  type  of  insulin  was  used)  and  there
as  no  statistical  analysis,  probably  due  to  the  sample
ize.
Hameed  et  al.19 assessed  height  separately  and  found
o  differences  after  insulin  therapy  initiation.  This  is  prob-
bly  due  to  the  result  seen  in  another  study  by  Bizzarri
t  al.22 They  suggest  that  in  the  development  of  CFRD  there
s  already  substantial  and  irreversible  impairment  of  height
ecause  most  patients  with  CF  develop  diabetes  at  puberty,
he  same  time  that  the  growth  spurt  occurs.22
The  evidence,  favorable  or  unfavorable,  to  the  use  of
nsulin  before  overt  diabetes  in  CF  patients  remains  incon-
lusive,  with  little  knowledge  about  long-term  results.  There
re  few  prospective  studies  on  the  use  of  insulin  before  overt
iabetes  in  patients  with  CF  and  they  include  population
ith  different  types  of  glucose  disorders,  without  age  group
elimitation,  follow-up  time,  and  insulin  type,  dosage,  and
mplementation  schedule.  Only  two  studies15,16 were  multi-
enter  and  only  three  were  controlled.15--17 Moreover,  it  was
ot  possible  to  assess  the  effect  of  important  variables,  such
s  nutritional  routine,  and  a  standard  deﬁnition  of  glycemic
isorders.
When  analyzing  the  results  of  studies  regarding  the
nabolic  effects  of  insulin,  there  are  theoretical  reasons  to
elieve  that  insulin  has  a  beneﬁcial  effect  on  the  population
tudied.  However,  the  addition  of  a  treatment  for  diabetes
n  a  multiple  drug  treatment  regimen  is  complicated,  which
akes  this  decision  even  more  controversial.
Multicenter  trials  in  randomized  pediatric  patients,  with
dequate  nutritional  support,  type  and  standard  doses  of
nsulin  (enough  to  promote  anabolism),  are  needed  to  deter-
ine  if  treatment  is  justiﬁed  or  not.  Keep  in  mind  that
lacebo-controlled  trials  are  difﬁcult  to  perform  due  to  the
act  that  insulin  is  an  injectable  medicine.
onclusion
he  different  methods  and  case  series  used  in  the  studies
o  not  allow  afﬁrming  that  early  insulin  therapy  should  be
pplied  in  patients  with  CF  and  glucose  disorders.  To  this
nd,  studies  with  larger  samples,  diet  standardization,  age
roup,  and  uniformity  of  insulin  use  are  needed.
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